Strong insurance growth, earnings pressure—macro headwinds compress profit

Delivered PAT 6296.7 Cr, YoY growth 18.2%

VNB ₹271 Cr, 87% YoY growth, 480 bps margin expansion

Reported 103.9% on old basis vs 120%+ industry, motor segment tactically slowed

AUM ₹5,46,944 Cr at 24% growth, PAT +27.6%, GNPA/NNPA improved

Management claims homemakers are immaterial; reserves built in via conservative loss assumptions

PAT ₹51 Cr down 70% YoY; management attributes to capital gains & GST, not underwriting

Original FY2026 guidance: breakeven within 1-2 years. Now: Finserv Direct Q4 FY27 (on track), Health Q4 FY28 (1-yr slip), Markets still loss-making. Requires sustained capex.

Management confirmed 'disciplined profitability over volume' stance; deliberately slowing motor GWP to manage loss ratios in soft pricing environment. Consistent with guidance.

VNB 87% growth, NBM 480 bps expansion (15.9% vs 11.1% prior year); Bajaj Life 2.0 strategy delivering. Guidance of accelerating profitable growth met.

April 2027 transition for insurance companies (1-yr forbearance granted). Management signals potential arbitrage on onerous contracts and long-term liability discounting.

Homemakers are immaterial in portfolio. Our reserves are already conservative; release TP reserves as book develops. GIC filed review petition; industry discussing price hike with regulator.

Industry credit quality improved over time. 50+ lenders, diversified risk. Trail revenue deals give direct insight; we're happy with results. Personal loans remain lead product.

Market is soft now; pricing will harden if catastrophes persist. We've always outperformed 16–18% better than market. Reduced motor exposure. Diversified portfolio, NATCAT reserves in place.

Direct: Q3/Q4 FY27 quarterly breakeven, FY28 full-year. Health: Q3/Q4 FY28 breakeven, FY29 full-year. Capex ₹200–300 Cr over next 6 quarters. ALTs, reinsurance will need larger capital.

Combination of both. MFI revival industry-wide. Added 20+ new partners in 15 months; reduced concentration from 50% to diversified base.

Structured approach: added riders same commission. Cost reduction from Bajaj Life 2.0 (21 months cost-saving) provides operating leverage.

Crop: Expected more tenders this year vs last. Govt health: 2+1 contract; we should get renewal. Volume depends on lives covered, overlap.

April 2027 effective date (1-yr forbearance). Key impacts: amortization of acquisition costs (both), long-term liability discounting (GI, big release), onerous contracts (GI arbitrage vs peers).

22% of NOPs have riders (term + savings). Intent to increase. Term riders 33–34%; multifaceted riders on PAR, non-PAR, ULIP as well.

Industry-wide phenomenon; Bajaj micro-segments geography-wise. Strategy: data-driven risk selection, ROI-adjusted capital model. Tactical slowdown while market is soft.

Management provided segment-level performance and emerging business capex guidance but no consolidated FY27 revenue guidance.

Life 2.0 cost reduction and product mix supporting margin accretion. General Insurance defensive underwriting strategy confirmed.

Direct approaching breakeven (no more capital needed). Health targeting breakeven by Q4 FY28 but requiring sustained investment.

Currently ₹31,444 Cr; needs 218% growth; market headwinds from soft equity market.

Industry-wide soft market (crop, fire, motor, health) pushing combined ratios to 120%+ while Bajaj maintains 103.9%. If cycle persists, even disciplined players face margin compression; if catastrophes force hardening, capital-constrained peers may exit, fragmenting market.

Motor own damage loss ratios trending upward across industry. Bajaj reduced motor GWP growth from 12% industry to ~10% this quarter; if loss ratios continue to accelerate, further volume sacrifice required or pricing discipline breaks.

Supreme Court ruling on homemaker third-party valuations (₹30,000 suggested); subsequent Punjab/Haryana HC rulings moderate impact but uncertainty remains. If applied broadly, could create reserve release/charge requirement; competitors like GIC filed review petition.

Finserv Direct, Health, Markets, and new ALT/Reinsurance ventures remain loss-making. Original FY2026 guidance: breakeven within 1-2 years. Now: Direct Q4 FY27 (tracking), Health Q4 FY28 (+1 year), Markets still unprofitable. Capex ₹200–300 Cr over 6 quarters required; reinsurance and ALTs need 'larger chunk' (unquantified).

In Q1 FY27, subdued equity markets yielded no realized gains, causing Bajaj General profit to drop 27% and Life PAT to fall 70% despite strong underwriting (GI COR stable, Life VNB +87%). This earnings quality issue masks operational performance and will reverse/amplify with market cycle.

Ind AS adoption (April 2027) brings acquisition cost amortization (life & GI), long-term TP liability discounting (GI), and onerous contract recognition (GI arbitrage vs peers but near-term volatility). RBI regulations on NBFC partnerships required Bajaj Health restructuring, impacting Q1 revenue slightly. GST hit Life margins by 290 bps.